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Inger Brandsma and Dik C van Gent*Abstract
Proper repair of DNA double strand breaks (DSBs) is vital for the preservation of genomic integrity. There are two
main pathways that repair DSBs, Homologous recombination (HR) and Non-homologous end-joining (NHEJ). HR is
restricted to the S and G2 phases of the cell cycle due to the requirement for the sister chromatid as a template,
while NHEJ is active throughout the cell cycle and does not rely on a template. The balance between both
pathways is essential for genome stability and numerous assays have been developed to measure the efficiency of
the two pathways. Several proteins are known to affect the balance between HR and NHEJ and the complexity of
the break also plays a role. In this review we describe several repair assays to determine the efficiencies of both
pathways. We discuss how disturbance of the balance between HR and NHEJ can lead to disease, but also how it
can be exploited for cancer treatment.
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Genomic integrity and faithful replication are essential
to prevent mutations and chromosomal rearrangements,
which may otherwise lead to diseases and in some cases
even death. DNA damage is generated by several differ-
ent genotoxic agents such as reactive oxygen species,
UV light from the sun and mutagenic chemicals [1].
These agents cause many types of DNA damage, ranging
from base damage to double strand breaks (DSBs). To
protect the genome from the deleterious effects of these
lesions, several mechanisms have evolved that detect
and repair DNA damage. Together with mechanisms
that regulate cell cycle progression and cell death path-
ways this is known as the DNA damage response (DDR).
In this review we concentrate on DSBs, which are
among the most cytotoxic types of DNA damage. The
therapeutic effect of several commonly used cancer
treatment modalities, such as ionizing radiation and the
chemotherapeutic doxorubicin, are based on the cell-
killing effect of DSBs. However, DSBs are also the initiat-
ing lesion of disease-causing chromosomal translocations
in cancer. Therefore, it is important to understand the
intricate regulation of the DDR upon DSB formation. We* Correspondence: d.vangent@erasmusmc.nl
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distribution, and reproduction in any mediummainly concentrate on the two main DSB repair path-
ways, Non-homologous end joining (NHEJ) and Hom-
ologous recombination (HR), with a special emphasis on
the balance between both repair mechanisms in health
and disease.
NHEJ
NHEJ is a relatively simple DSB repair pathway (Figure 1).
Both ends of the break are first bound by the Ku70/Ku80
heterodimer, which then recruits the catalytic subunit
of the DNA dependent protein kinase (DNA-PKcs) [2].
If necessary, the ends can be trimmed by nucleases (such
as Artemis) or filled in by DNA polymerases (such as
Polμ or Polλ) to create compatible ends [3]. Finally, the
ligation complex, consisting of DNA ligase IV, X-ray
cross-complementation group 4 (XRCC4) and Xrcc4 like
factor (XLF)/Cernunnos ligates the ends [4,5]. NHEJ can
take place throughout the cell cycle. For an extensive
review on NHEJ see [3].
HR
HR uses a sequence similar or identical to the broken
DNA as a template for accurate repair. The sister chro-
matid is used as an identical template in the S and G2
phases of the cell cycle, when the DNA has been repli-
cated. HR is restricted to these cell cycle phases ined Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,



























Figure 1 HR and NHEJ. NHEJ) NHEJ starts with recognition of the DNA ends by the Ku70/80 heterodimer, which recruits DNA-PKcs. If the ends
are incompatible, nucleases such as Artemis can trim the ends. The XRCC4-DNA Ligase IV-XLF ligation complex seals the break. HR) The MRN-
CtIP-complex starts resection on the breaks to generate single stranded DNA (ssDNA). After resection the break can no longer be repaired by
NHEJ. The ssDNA is first coated by RPA, which is subsequently replaced by Rad51 with the help of BRCA2. These Rad51 nucleoprotein filaments
mediate strand invasion on the homologous template. Extension of the D-loop and capture of the second end lead to repair.
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(repetitive) non-identical sequences. Spurious HR can
lead to loss of heterozygosity (when HR takes place be-
tween paternal and maternal chromosomes) or inser-
tions/deletion (when repeats are not aligned properly).
The HR pathway starts with resection of the broken
DNA ends (Figure 1) by the MRN-complex [6,7], to-
gether with CtBP-interacting protein (CtIP) [8,9] and
other exonucleases, generating 3’-single stranded DNA
(ssDNA) [9,10]. The ssDNA tail is coated by Replication
protein A (RPA) to remove secondary structure [11].
Subsequently, BRCA2 mediates the replacement of RPA
by RAD51, to form a nucleoprotein filament that
searches for the homologous sequence on the sister
chromatid. After strand invasion, catalyzed by RAD51
and many other proteins, the DNA end is extended
using the intact sequence as a template. After restoration
of any lost sequence information, the second end of the
broken DNA is captured and the junctions are resolved
to give a precisely repaired DSB [12]. This resolutionstep can be accomplished via formation of two Holiday
junctions, which are subsequently resolved to give cross-
over or non-crossover products (the double Holiday
junction model). An alternative HR model, the synthesis
dependent strand annealing (SDSA) model, does not in-
volve Holiday junctions and results in non-crossover
products only [13].Foci
Microscopically, DSBs can be visualized as local spots of
repair protein accumulation (also called foci) in the nu-
cleus. For example, histone H2AX is phosphorylated lo-
cally around the DSB and 53BP1, RPA and RAD51
accumulate in foci after ionizing radiation. Changes in
the number of foci per nucleus in time can be quantified
to analyze the dynamics of DNA repair [14]. Not all re-
pair proteins accumulate in sufficient numbers to form
foci. For example Ku70/80 does not form foci, although
it is recruited to DNA damage [15,16].
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In addition to classical HR, several subpathways result
in slightly different products. For example the single
strand annealing (SSA) pathway uses directly repeated
stretches of homology to repair DSBs. After resection
of the break (as described above for HR) complemen-
tary stretches in the ssDNA anneal and the intervening
sequence and one of the repeats is deleted [17]. Since
HR and SSA use the same substrate, these pathways
compete when repeats are present on both sides of the
break and SSA should be suppressed to prevent its
mutagenic effect.
Alternative end-joining pathways can also join DSBs
in an error-prone manner, especially when classical
NHEJ is impaired by deletion of essential components.Figure 2 NHEJ repair assays. a) Linear plasmid DNA with 6 bp repeats at
and digested using BstXI to distinguish between direct repair and microho
results in restoration of GFP expression. c) Cleavage by I-SceI and subseque
(SD and SA) and the adenoviral exon (AD), resulting in the expression of ac
substrate. Repair of the oppositely oriented I-SceI breaks results in loss of H
substrate expresses GFP, while the repaired substrate allows expression of R
a translation start site is located, preventing translation of the XHATM resist
results in XHATM resistance. The sequence around the breaks can be seque
assay. Cleavage by the Rag1/2 endonuclease at the recombination signal s
indicate location of PCR primers to amplify joints [21].The genetics of this pathway are not well defined and
there may even be several alternative end-joining path-
ways. A dependence on DNA ligase III, Xrcc1 and
PARP1 has been found in genetic assays [18,19]. How-
ever, in another assay the repair of I-SceI induced DSBs
in XRCC4-deficient pro-B cell lines did not require
Xrcc1 [20]. Alternative pathways show increased DSB
joining using microhomologies (stretches of 1–6 bp of
direct repeat at the junction), possibly to stabilize the
synapsed ends [3].
Although these alternative DSB repair pathways can
work in specific experimental settings, they probably do
not play a major role in repair of most DSBs in wild type
cells. Therefore this review will focus on the balance be-
tween the classical forms of HR and NHEJ.the ends is joined after transfection. The joints are amplified by PCR
mology mediated repair [21]. b) Repair of linearized plasmid DNA
nt repair lead to loss of the middle splice donor and acceptor sites
tive GFP [22]. d) H2Kd fused to CD8 is expressed from the intact
2Kd-CD8 and allows expression of CD4 [23]. e) Similar to d), the intact
FP and loses GFP expression [24]. f) Between the opposite I-SceI sites,
ance gene. Repair of the I-SceI breaks and loss of the intervening ATG
nced to monitor loss of nucleotides [25]. g) V(D)J recombination
equences induces inversion of the intervening sequence. Small arrows
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To study the balance between HR and NHEJ, one would
ideally measure both types of repair at the same time
using a defined chromosomal site. Unfortunately such
an assay is not yet available. There are, however, many
assays to measure HR and NHEJ separately. A good
understanding of these assays is indispensable for cor-
rect interpretation of the results obtained using these
different approaches. We therefore review the major
assay systems and discuss their merits and drawbacks.
Assays to measure NHEJ
NHEJ can be measured in many different ways. The sim-
plest version is transfection of linearized DNA into wild
type and mutant cells. Joining of the ends can be moni-
tored by cloning out individual plasmids or PCR amplifi-
cation followed by sequencing or digestion of the
junction [21] (Figure 2a). Recircularization can also be
monitored by following the restoration of expression of
a reporter gene, such as an antibiotic resistance gene or
a fluorescent marker (Figure 2b). A major disadvantage
of these assays is that the linear DNA is extrachromo-
somal and NHEJ cannot be measured in the normal con-
text of chromatin. However, it is a simple assay that can
monitor decreased activity of the core NHEJ machinery
as a shift towards microhomology use at the newly
formed junctions.
Another type of NHEJ assays uses two I-SceI restric-
tion sites. These sites can be in the same or opposite
orientation, generating compatible or incompatible ends,
respectively. These constructs are generally integrated
into the genome. The general theme of all these assays is
restoration of expression of a marker gene, in some
cases accompanied by inactivation of another gene. Mao
et al. (Figure 2c) interrupted the GFP gene with an in-
tron containing an adenoviral exon (AD) flanked by two
I-SceI sites. Repair of the two I-SceI induced DSBs leads
to loss of the intervening exon and expression of func-
tional GFP [22]. Guirouilh-Barbat et al. developed a
similar assay (Figure 2d) with compatible or incompat-
ible I-SceI sites, but they used surface antigens as a
read-out for repair [23]. Coleman and Greenberg also
used a comparable assay (Figure 2e) with GFP between
the I-SceI sites and RFP downstream, resulting in loss of
GFP and expression of RFP after repair of the I-SceI
induced DSBs [24]. In these assays with a double I-SceI
site it is also possible to sequence the joints and to de-
termine the loss of nucleotides around the breaks
(Figure 2f ) [25].
A disadvantage of these assays using I-SceI restriction
sites is that the individual I-SceI break has compatible
ends and can recreate an I-SceI site if it is repaired pre-
cisely by NHEJ. Therefore, several cycles of cleavage and
repair can happen before the site is lost due toinaccurate repair and these assays cannot measure the
NHEJ efficiency accurately. However, sequencing of the
junctions can provide interesting information about im-
precise end-joining events. To avoid the cut-and-paste
cycle problem of the I-SceI sites, some assays use trans-
poson excision to create a break. Repair of transposon-
induced DSBs can reveal details of efficiency as well as
precision of NHEJ [26,27]. In principle, transposons would
also be useful to study HR, although their DSB formation
efficiency is generally lower than endonucleases.
The immune system depends on end-joining for V(D)J
and class switch recombination (CSR). Pan-Hammarstrom
and colleagues studied CSR by PCR amplification and
sequencing of the junctions in normal individuals and
patients. They found that patients with mutations in
NHEJ components, such as DNA ligase IV, showed an
increased dependence on longer microhomology stretches
at the junctions [28]. An advantage of this assay is that
repair is measured on endogenous substrates. However,
it is not clear whether these loci are representative for
other types of DSBs.
V(D)J recombination also depends on NHEJ factors to
repair the breaks induced by the Rag1 and Rag2 pro-
teins. This type of repair can be assayed using a specific
repair substrate containing Recombination Signal
Sequences, the recognition sites for Rag1 and Rag2
(Figure 2g) [21]. The V(D)J recombination assay gives a
clear phenotype for defects in proteins involved in DNA
end-processing, such as the Artemis nuclease [29]. The
major disadvantage of these types of assays is the special
nature of the DSBs formed by the RAG proteins, which
may shuttle the breaks towards NHEJ [30].
Assays to measure HR
The most commonly used assay to measure HR is
the DR-GFP assay developed by Pierce and Jasin [31]
(Figure 3). The reporter construct can be inserted by
gene targeting or random integration. It contains two
GFP sequences separated by a selection marker. The
5’ GFP sequence is inactivated by an I-SceI site and
internal stop codons, preventing GFP expression. The
3’ truncated GFP serves as a template for repair after
DSB induction by I-SceI. Repair of the break by gene
conversion using the downstream GFP sequence leads
to restoration of the GFP gene and the percentage of GFP
expressing cells can be determined by FACS analysis.
This HR assay has been used successfully to
characterize defects in various (repair) mutant genetic
backgrounds. An important advantage of this HR assay
is that it measures repair using a chromatinized reporter
construct in the chromosome. However, the template for
repair is downstream of the break, whereas the normal
template for HR is the equivalent position on the sister







Before break After repair
puro resistance
Figure 3 HR Assay. The 5’ GFP is inactivated by several in frame stop codons and contains an I-SceI site. A downstream truncated GFP, lacking
the I-SceI sites and stops, serves as a template. Accurate repair via HR results in GFP expression.
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restoration of the sequence using the sister chromatid as
a repair template, which leaves a high degree of uncer-
tainty about the relative levels of HR and NHEJ.
Expression of I-SceI is usually induced by transfection of
an expression plasmid into an asynchronously growing cell
population. This creates DSBs in the reporter substrate
throughout the cell cycle, whereas HR only takes place in
the S and G2 phases. To overcome this problem, Hartle-
rode et al. developed an I-SceI fusion protein that is drug-
activatable. Enriching cells in a certain phase of the cell
cycle then allows restricted activation of I-SceI [32].
HR can also be estimated by scoring sister chromatid
exchanges (SCEs). In this assays a nucleotide analog is
added in the first cell cycle to allow incorporation into
the newly synthesized strand in S phase. After a second
replication round, only one of the sister chromatids is la-
beled, which allows visualization of recombination be-
tween the sister chromatids in metaphase spreads by
staining for the incorporated nucleotide analog. SCEs
can be formed in S phase during the repair of collapsed
replication forks as well as in G2 phase at two-ended
DSBs [33].
A completely different method to assess the efficiency
of DSB repair is monitoring the disappearance of
γH2AX foci. These foci form within a few minutes after
DSB formation and disappear slowly as repair takes
place. By comparing the kinetics of several known HR
and NHEJ mutants, the efficiency and likely repair path-
way can be determined. For a review on the advantages
and potential pitfalls of this assay, see [34].
As a more sophisticated approach, the formation and
disappearance of 53BP1-YFP and Rad52-Cherry foci has
been followed to estimate the use of HR and NHEJ in
single cells throughout the cell cycle [35]. Karanam et al.
found that there is a gradual increase in HR at the be-
ginning of S phase. The number of Rad52 foci increases
till mid S phase and then decreases towards the end of
S phase. In G2, very few Rad52 foci were observed,
showing that HR is not the predominant pathway in G2.
This is consistent with data from Beucher et al., who
demonstrated that NHEJ repairs approximately 85% of
all IR-induced DSBs in G2, as measured by γH2AX foci
kinetics [36].Balancing HR and NHEJ
The presence of large numbers of highly repetitive
sequences in the DNA of higher eukaryotes makes HR
between sequences other than sister chromatids prone
to misalignment of the homologous sequences. There-
fore, HR generally dominates in organisms with a small
genome (with low abundance of repetitive sequences),
whereas mammals mainly rely on NHEJ for DSB repair
[35,37]. However, even in highly complex genomes, HR
is used as the preferred DSB repair mechanism to deal
with DSBs that are formed during replication. This
necessitates intricate control mechanisms to prevent ac-
cess of the wrong repair pathway to the DSB.
Resection & cell cycle
HR can only safely be used to repair breaks in the S and
G2 phases of the cell cycle. The first mechanism to regu-
late this depends on S/G2 specific cyclin dependent
kinases (CDKs). DNA end resection requires phosphor-
ylation of CtIP on a CDK consensus sequence [9,38,39].
Proteasome-mediated degradation of the CtIP protein in
G1 [40] adds an additional layer of regulation at the re-
section step.
CDK1/CyclinB also phosphorylates the NBS1 compo-
nent of the MRN complex on Serine 432 during the S, G2
and M phases, which is required for resection and efficient
HR. However, IR sensitivity was not affected in the
Ser432Ala NBS1 mutant, consistent with the notion that
NHEJ is the major DSB repair pathway in mammals [41].
Although activation of HR proteins in a cell cycle
dependent manner helps to restrict their activity, it is insuf-
ficient to ensure safe use of HR. While replication is on-
going in the S phase, parts of the genome have not yet
been replicated and recombination of these parts should
be avoided to prevent loss of heterozygosity and non-allelic
recombination. Therefore, another layer of regulation is
provided by the structural maintenance of chromosomes
(SMC) proteins such as Cohesin, Condensin and SMC5/6:
they are able to confine repair to the sister chromatid and
prevent HR between other sequences [42,43].
Complexity of the break
Whether HR or NHEJ is used also depends on DSB
complexity. This phenomenon has been studied in detail
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NHEJ contribute to DSB repair. Treatment of cells with
the topoisomerase II inhibitor Etoposide results in
breaks with a 4 bp 5’-overhang with covalently attached
protein [44]. The large majority of these breaks are
repaired rapidly by NHEJ. The remaining 10% of the
Etoposide induced breaks is repaired with slow kinetics
via HR [45]. High linear energy transfer (LET) carbon
ions, on the other hand, induce highly complex clusters
of DSBs and other types of DNA damage [46], because
this type of radiation causes a high number of ioniza-
tions in a small volume. These breaks are frequently
resected and their repair takes place via HR with slow
kinetics [45]. From the breaks induced by low LET ion-
izing irradiation (IR), which causes less complex DSBs,
only 20-30% is resected and their repair is much less
dependent on HR [36,45].
The chromatin structure around the DSB affects repair
as well. Breaks in heterochromatin are repaired more
slowly than breaks in euchromatin [47] probably because
euchromatin is more easily accessible for repair and
requires less or no remodeling. Repair of breaks in het-
erochromatin requires ATM [47]. ATM phosphorylates
transcriptional corepressor Krüppel-associated box
(KRAB)-associated protein (KAP)-1 [48], which disrupts
the interaction between Kap-1 and CHD3 [49]. CHD3 is
an ATP-dependent nucleosome remodeling enzyme and
its dispersion allows chromatin relaxation, facilitating
DSB repair in heterochromatin. Furthermore, the ATP-
dependent chromatin remodeler SMARCAD1 can also
be recruited to sites of DNA damage where it facilitates
resection [50].
Genetic factors influencing pathway choice
The core HR and NHEJ machineries have been con-
served from yeast to mammals [51]. However, several
genes have been added to optimize or regulate both path-
ways in higher eukaryotes. For example, NHEJ has
acquired DNA-PKCS and HR added several RAD51 para-
logs. Furthermore, several additional genes in higher
eukaryotes regulate DSB repair pathway choice without
direct participation in the catalytic steps of the repair
reaction.
53BP1
The p53 binding protein 1 (53BP1) is recruited to DSBs,
where it has functions in cell cycle checkpoint mainten-
ance and double strand break repair [52]. The fast phase
in DSB repair is normal in the absence of 53BP1, but re-
pair of breaks in heterochromatin is severely impaired,
probably as a result of impaired Kap1 phosphorylation
[49,53].
A deeper understanding of the 53BP1 function has
been gained from studies in the immune system. Duringclass switch recombination, highly repetitive DNA seg-
ments are recombined to generate the different classes
of antibodies. DSBs generated during this recombination
reaction can be repaired via NHEJ or alternative end
joining. In the absence of 53BP1, resection increases and
microhomology mediated alternative end-joining takes
over from classical NHEJ [54]. In V(D)J recombination,
Variable (V), Diversity (D) and Joining (J) segments are
recombined to create a large variety of functional coding
sequences for immunoglobulins and T-cell receptors.
DSBs created by Rag1/2 are repaired via NHEJ. 53BP1
prevents extensive degradation and it promotes synapsis
of DNA ends and stabilizes long-range interactions, not
only between breaks created during V(D)J recombin-
ation [55], but also between deprotected telomeres [56].
BRCA1 and associated protein
In contrast to the NHEJ promoting effect of 53BP1, the
tumor suppressor BRCA1 is required for efficient HR
[57] and formation of Rad51 foci after DSB induction
[58]. BRCA1 is an E3-ubiquitin ligase that forms a com-
plex with the E2 enzyme BARD1 via its RING domain.
This interaction is required for the ligase activity, as well
as protein stability and nuclear localization [59]. Al-
though several RING domain mutations have been found
in patients, it is currently unknown how the HR defect is
related to the E3-ligase function and BARD1 interaction.
Drost et al. recently showed that the ring domain is
necessary for tumor suppression, but not required for the
development of resistance to chemotherapeutics. Tumors
with a C61G mutation in the RING domain rapidly de-
velop resistance to platinum drugs and the PARP inhibitor
Olaparib, while retaining this mutation [60].
In addition to its function as a ubiquitin ligase, BRCA1
may also function as a scaffold protein that associates
with many interaction partners, such as Abraxas,
BACH1 and BRCA2/PALB2 [59]. For efficient resection
of DNA ends, its interaction with CtIP and the MRN
complex is probably important [39,61]. BRCA1 also
interacts with RAP80 and the BRCA1/RAP80 complex
is recruited to ubiquitylated chromatin around DSBs
[62-64]. In contrast to the BRCA1 interactions described
above, the RAP80-BRCA1 interaction decreased HR: de-
pletion of Rap80 stimulated recruitment of CtIP and
Mre11 and thereby resection [24]. The BRCA1 interac-
tions with CtIP and RAP80 are mutually exclusive, indi-
cating that competition for this BRCA1 binding site
affects resection and thereby pathway choice. For
replication-associated breaks, BRCA1 clearly tips the
balance towards HR.
Genetic interactions of BRCA1 and 53BP1
Recently, some unexpected genetic interactions between
BRCA1 and 53BP1 shed new light on their function in
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causes embryonic lethality, but this can be rescued by
deletion of 53BP1 [65]. Unexpectedly, deletion of 53BP1
also restored HR and Rad51 foci formation in BRCA1
deficient cells [66,67], implying that both factors influ-
ence HR in opposite directions and that inactivation of
both genes largely restores the balance. Inactivation of
53BP1 in BRCA1−/− ES cells led to an increase in both
nucleolytic DNA end processing and RPA phosphoryl-
ation [67]. ATM inhibition in BRCA1 −/− 53BP1−/− cells
reduced RPA phosphorylation and Rad51 foci formation,
indicating that ATM-dependent resection allows partial
restoration of HR [67].
Figure 4 presents a plausible model to accommodate
these findings. One-ended DSBs that are formed during
replication require BRCA1 to stimulate resection. In
BRCA1 deficient cells, 53BP1 prevents resection of DNA
ends, leading to aberrant diversion of breaks to NHEJ.
This creates dead-end products (if only one DNA end
is present) or inappropriate joining to distant sequences
causing chromosomal translocations (if a DNA end com-
bines with an unrelated other DNA end). Two-ended
DSBs, on the other hand, require 53BP1 to limit resec-
tion and allow efficient NHEJ. Overactive resection in
53BP1−/− cells may result in aberrant HR reactions (such
as single-strand annealing) or alternative end-joining
pathways, creating microhomology-mediated transloca-
















Figure 4 BRCA1 and 53BP1 in DSB repair. a) Repair of replication associ
break in BRCA1 deficient cells, preventing repair via HR. The breaks are eith
which leads to chromosomal rearrangements and genomic instability. In th
faithful repair via HR. b) IR induced two ended DSBs are mainly repaired via
end-joining (alt-EJ). Repair via HR or alt-EJ increases when classical NHEJ isFurther insight into the role of BRCA1 and 53BP1
in repair pathway choice was recently obtained using
super resolution microscopy of IR induced foci (IRIF).
The core of the focus contained mainly 53BP1 mole-
cules in the G1 phase of the cell cycle, probably repre-
senting repair via NHEJ. In S phase, however, the core
of the IRIF was filled with BRCA1 and 53BP1 formed
a ring around this core, suggesting that BRCA1 phys-
ically excludes 53BP1 from the break to allow repair
via HR [70].
BRCA1 deficient cells are exquisitely sensitive to PARP
inhibitors, which inhibit single strand break repair
[71,72]. The rationale for this observation is that rep-
lication of DNA with single strand breaks results in
formation of single DNA ends, which require HR for
their repair (Figure 4). As described above, deletion
of 53BP1 in BRCA1 deficient cells rescues embryonic
lethality. However, loss of 53BP1 also leads to resist-
ance to PARP inhibition [66,73]. In the BRCA1-
deficient cells that have also lost 53BP1, the number of
chromosome and chromatid breaks is decreased and
checkpoint activation is diminished compared to cells
that are only BRCA1 deficient [66], suggesting that the
regained HR capacity in these cells is largely suffi-
cient to restore genomic stability. A subset BRCA1 and
BRCA2 mutant tumors shows loss of 53BP1, indicating
that therapy resistance via loss of 53BP1 may be clinic-
ally relevant [66].IR induced DSB
53BP1 BRCA1
CtIP/MRN
Repair via NHEJ Resection
HR or alt-EJ
b
ated breaks requires HR. 53BP1 blocks resection of the one-ended
er left unrepaired or repaired via NHEJ using other random DNA ends,
e absence of 53BP1, resection of the DNA ends can take place, allowing
NHEJ, however part of the breaks is repaired via HR or alternative
impaired by a mutation in one of the core NHEJ genes or 53BP1.
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Ubiquitin and the small ubiquitin-like modifier (SUMO)
are small polypeptides that can be attached to proteins
as a posttranslational modification. After activation of
ubiquitin or SUMO by an E1 enzyme, they are trans-
ferred to an E2 conjugating enzyme. With the help of an
ubiquitin (or SUMO) ligase (E3) the modification is
attached to the substrate. Deubiquitylating enzymes
(DUBs) can reverse the ubiquitin modification.
Many proteins involved in the DDR can be ubiquity-
lated or sumoylated [2,74-76]. For the sake of simplicity,
we will focus on one part of the DDR signaling cascade
as an example. Upon DSB formation, histone H2AX is
phosphorylated by ATM or DNA-PK. MDC1 is recruited
to this phosphorylated histone (γH2AX) and is in turn
phosphorylated by ATM. This attracts the E3 ligase
RNF8 which ubiquitylates H2A and H2AX. Subsequent
action of the E3 ligase RNF168 leads to more extensive
ubiquitylation of the chromatin around the break, creating
a recruitment platform for many other repair proteins,
including 53BP1 and BRCA1 [77]. These ubiquitylation
events are also required for phospho-KAP-1 foci for-
mation and thereby chromatin relaxation at sites of
damage [53].
In addition to an effect on recruitment of repair pro-
teins, ubiquitylation can also affect release of proteins
from the lesion. The transient binding of Ku at DNA
ends affects pathway choice. Ku binds in all phases of
the cell cycle and must be removed to allow resection
[78,79]. This removal can be facilitated via ubiquitlyation
of Ku by the E3 ligase RNF8 and an unknown E2 conju-
gating enzyme, leading to proteasome-dependent Ku
degradation [80]. Since Ubiquitylation is a very abundant
modification on DDR proteins, it is likely that more
modifications affecting pathway choice will be discov-
ered in the future.Concluding remarks
A unifying model for DSB repair pathway choice should
take into account that NHEJ is relatively fast, while re-
section is a slow process that probably creates a point of
no return. Therefore, it is to be expected that NHEJ ini-
tially tries to repair all DSBs and only if this repair path-
way fails to repair the lesion, the chance that resection
takes place increases over time, necessitating repair via
HR. This is consistent with the observation that the
binding of the Ku heterodimer to DNA ends is a very
fast process, but the assembly of end-joining complexes
is dynamic and may in the long run give way to proteins
mediating resection if they are active [16]. This means
that initiation of HR will mainly be restricted to the S
and G2 phases of the cell cycle, when CtIP is active. In-
deed, a subfraction of DSBs in G2 requires BRCA2 fortheir repair, but knock-down of both CtIP and BRCA2
alleviates this repair defect [45], suggesting that avoiding
resection prevents HR and allows repair of these DSBs
by NHEJ. Replication associated breaks, on the other
hand, should be channeled to HR, which is the only
pathway that can restart a replication fork from a single
broken DNA end.
The study of the balance between HR and NHEJ is im-
portant for the prediction of treatment responses upon
inhibition of these pathways in various genetic back-
grounds. Combined treatments might backfire when the
balance is tipped the wrong way. For example, the treat-
ment of BRCA1 and BRCA2 deficient cells is most ef-
fective when NHEJ is functional, whereas impaired
NHEJ prevents lethal genomic instability and cytotox-
icity, which counteracts the effect of PARP inhibitors in
HR deficient cells [73,81].
The balance between HR and NHEJ is heavily regu-
lated, but the wiring and hierarchy of this regulatory
network is still incompletely understood. Development
of targeted therapies using DNA damage response
defects requires a much more detailed knowledge of
the precise network of the cellular responses to DNA
damaging treatments. It is to be expected that new
assay systems will be developed and that a flurry of
novel combinations of chemical inhibitors and genetic
defects will increase our understanding of these pro-
cesses in the near future. This knowledge will then be
an invaluable source for developing new targeted ther-
apies for tumors with DNA damage response defects,
which should yield more specific and effective thera-
peutic approaches to combat cancer. Novel tools to
characterize tumor-specific (DNA repair gene) muta-
tions, such as whole genome sequencing approaches,
should then bring truly personalized medicine for can-
cer treatment within reach.
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